HL-60 Human Promyelocytic Leukemia Cell Line (HL-60)

HL-60 is a human promyelocytic leukemia cell line established from the peripheral blood of a 36-year-old woman diagnosed with acute myeloid leukemia. HL-60 cells display a neutrophilic promyelocyte morphology, proliferate in suspension, and can be induced to undergo differentiation into multiple myeloid lineages (granulocytes, monocytes, macrophages) using various agents such as dimethyl sulfoxide, retinoic acid, phorbol esters, or vitamin D3[1][3][4][5][7][8]. The cell line is characterized by genetic instability, amplification of the c-myc oncogene, absence of functional p53, and responsiveness to both physiologic and pharmacologic differentiation stimuli[5][4]. HL-60 cells are extensively used as a model for leukemia research, especially for investigating the molecular pathways of myeloid differentiation, drug screening, toxicity assessment, chromatin and transcriptional changes, and signaling mechanisms relevant to both normal and malignant hematopoiesis[1][4][7]. Unlike a molecular target (such as a receptor or enzyme), HL-60 serves as an experimental system rather than a direct therapeutic target, and thus should not be treated as a druggable molecule itself[1][3][4][7][8].

Other names

HL60HL-60Human Leukemia 60HL-60 cell lineHL60 cell line

Induction of differentiation, Apoptosis, Modulation of signaling pathways, Cytotoxicity (not direct targeting of 'HL60')